Mark Pruzanski - Director, Intercept Pharmaceuticals, Inc

As of October 4, 2021


Mark Pruzanski Net Worth

  • Net worth is estimated to be at least $66.41M
  • Owns at least 566,829 units of Intercept Pharmaceuticals, Inc stock
  • Sold an estimated value of $64.28M in the last 9 years at Intercept Pharmaceuticals, Inc

Mark Pruzanski Compensation at Intercept Pharmaceuticals, Inc in 2020

  • Earned a $757,850 salary
  • Rewarded $4,113,504 in stock value and options
  • Received a total compensation of $6,427,005

Mark Pruzanski Trading

  • Largest purchase of shares was 50,000 units , worth over $632.98K on November 27, 2019
  • Largest sale of shares was 35,000 units , worth over $5.78M on September 22, 2016
  • In total has made about 75 transactions over 9 years
  • Usually trades in January and July, with the busiest year in 2014
Ticker
Type
Value
Price per Share
Shares
Filing Date
No matching records found
1

Mark Pruzanski Mailing Address

  • Mailing address is C/o Intercept Pharmaceuticals, Inc. 18 Desbrosses St. New York NY 10013 NY

Intercept Pharmaceuticals, Inc Executive Compensation

Name
Year
Salary
Bonus
Stock Awards
Option Awards
Other Earnings Plans or Compensations
Other Compensation
Total
Mark Pruzanski, M.D., 2020 $757,850 - $4,113,504 $1,015,996 $531,995 $7,660 $6,427,005
Mark Pruzanski, M.D., 2019 $734,292 - $4,197,742 $1,116,118 $560,265 $7,368 $6,615,785
Mark Pruzanski, M.D., 2018 $702,000 - $1,667,718 $1,705,358 $442,260 $8,623 $4,525,960
Jerome Durso, 2020 $599,524 - $2,057,016 $998,776 $231,737 $21,910 $3,908,963
Jerome Durso, 2019 $573,250 - $2,089,570 $1,238,321 $359,284 $21,368 $4,281,793
Jerome Durso, 2018 $540,800 - $1,554,326 $775,844 $292,032 $22,403 $3,185,406
Sandip Kapadia, 2020 $476,863 - $1,087,836 $528,088 $184,039 $21,910 $2,298,736
Sandip Kapadia, 2019 $464,100 - $1,001,664 $586,573 $252,935 $21,368 $2,326,640
Sandip Kapadia, 2018 $442,000 - $790,164 $393,544 $228,735 $22,403 $1,876,846
Richard Kim, 2020 $456,095 - $1,044,360 $505,128 $168,056 $79,211 $2,252,850
Richard Kim, 2019 $442,900 $202,800 $890,368 $521,398 $265,519 $76,343 $2,399,328
Lisa Bright, 2020 $480,552 - $925,704 $453,467 $240,955 $139,106 $2,239,784
Ryan Sullivan, 2020 $437,107 - $1,087,836 $528,088 - $89,942 $2,142,973
Ryan Sullivan, 2019 $445,520 - $1,471,902 $871,713 $267,089 $21,368 $3,077,592
Ryan Sullivan, 2018 $376,158 - $1,239,112 $1,190,351 $229,122 $173,437 $3,208,180
Christian Weyer, M.D., M.A.S., 2020 $486,731 - $925,704 $453,467 $170,804 $21,910 $2,058,616
No matching records found

Source: https://www.sec.gov/Archives/edgar/data/1270073/000110465921055639/tm218121-2_def14a.htm

Intercept Pharmaceuticals, Inc Insider Trading

  • The most recent transaction was 237,000 units bought on March 12, 2021 by Srinivas Akkaraju worth over $5.02M
  • In the last 9 years, insiders at Intercept Pharmaceuticals, Inc sold an estimated value of $1.66B and bought an estimated value of $148.52M
  • The most active traders are David Shapiro, Chief Medical Officer,  Mark Pruzanski, Director,  and Lisa Bright, President
  • Insider trading is most common in January, with the busiest year in 2019

INTERCEPT PHARMACEUTICALS, INC. Insider Trades

Insider Names
Type
Value
Price per Share
Shares
Filing Date
No matching records found
1